DCDana Farengo Clark

Dana Farengo Clark

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dana Farengo Clark has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of breast cancer polygenic risk score disclosure on decisional conflict around risk-reducing mastectomy in women with pathogenic BRCA1/2 variants

    by Giulia Ongaro, Caroline Salafia, Rania Sheikh, Elizabeth Schofield, Dana Farengo Clark, Jessica Ebrahimzadeh, Anu Chittenden, Jill E. Stopfer, Jamie Brower, Heather Symecko, et al.

  • Open Access

    The Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in BRCA1/2 Carriers

    by Giulia Ongaro, Caroline Salafia, Rania Sheikh, Elizabeth Schofield, Dana Farengo Clark, Jessica Ebrahimzadeh, Anu Chittenden, Jill E. Stopfer, Jamie Brower, Heather Symecko, et al.

    Purpose: Female BRCA1/2 carriers face high breast cancer risks and complex preventive decisions, which can generate decisional conflict. Polygenic Risk Scores (PRS) offer individualized risk estimates that may support decision-making. We examine whether PRS disclosure reduces decisional conflict in BRCA1/2 carriers and whether PRS magnitude interacts with numeracy and tolerance for ambiguity. Methods: Unaffected BRCA1/2 carriers ( N= 354) were assessed pre PRS disclosure (T0), one-week (T1), and six-months post-disclosure (T2). PRS were translated into 10-year and lifetime absolute breast cancer risk estimates. Mixed-effects models tested changes in decisional conflict, and regression/moderation analyses tested PRS effects and interactions with numeracy and tolerance for ambiguity. Results: Decisional conflict decreased significantly after PRS disclosure. Higher 10-year risk was associated with greater decisional conflict immediately after disclosure. Lifetime risk alone did not predict conflict. Tolerance for ambiguity moderated the effect of lifetime risk at T1: women with low/average tolerance experienced higher conflict with high PRS and lower conflict with low PRS. Numeracy, age, and family cancer history did not moderate PRS effects. Conclusion: Decisional conflict decreased post-PRS disclosure, with short-term responses influenced by tolerance for ambiguity. Findings suggest that PRS can complement standard BRCA1/2 genetic counseling and highlight the need for tailored risk communication.


  • Open Access

    An eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Patients With Metastatic Cancers: Protocol for a Randomized Trial

    by Kimberley T Lee, Briana McLeod, Brian Egleston, Sarah Brown, Sarah Howe, Dominique Fetzer, Lauren Gutstein, Cara Cacioppo, Dana Clark, Susan M Domchek, et al.

    Background: Germline BRCA1 and BRCA2 testing is a standard evidence-based practice, with established risk reduction and cancer screening guidelines for genetic carriers. With Food and Drug Administration approval for poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors in patients with metastatic breast, ovarian, pancreatic, and prostate cancer, there is an additional therapeutic rationale for testing all patients with these cancers for germline BRCA1 and BRCA2 mutations. However, many at-risk patients do not have access to genetic services, leaving many genetic carriers unidentified. Objective: The eREACH (A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate, and Pancreatic Cancer Patients) study evaluates the effectiveness of a theoretically and stakeholder-informed eHealth (eg, digital) delivery alternative to traditional genetic counseling for patients with metastatic breast or prostate cancer or advanced or metastatic ovarian or pancreatic cancer referred for genetic testing to determine whether they are candidates for a PARP inhibitor. Methods: The eREACH study is a randomized noninferiority study using a 2 × 2 design to test a self-directed digital intervention to deliver clinical genetic testing for patients with metastatic cancers. The traditional standard-of-care pretest (visit 1) and posttest (visit 2—disclosure) counseling delivered by a genetic counselor is replaced with our patient-informed digital intervention. The four arms were as follows: arm A, genetic counselor for visits 1 and 2; arm B, genetic counselor for visit 1 and digital intervention for visit 2; arm C, digital intervention for visit 1 and genetic counselor for visit 2; and arm D, digital intervention for both visits. Participants were adults with advanced or metastatic breast, ovarian, pancreatic, and prostate cancer. The primary outcomes of this study were change in genetic knowledge and anxiety from baseline to postdisclosure assessment. We will test whether the digital intervention is noninferior to standard-of-care counseling with a genetic counselor using a modified noninferiority ANOVA of the posttest disclosure minus baseline change scores. In secondary analyses, we will test pairwise differences among the 4 groups. Results: As of January 2025, we have completed enrollment of 229 participants. Data analysis is ongoing, and we expect the results to be published in 2025. Conclusions: Increasing indications for BRCA1 and BRCA2 testing create a pressing need to evaluate alternative delivery models to increase access and uptake of these tests while maintaining adequate patient cognitive, affective, and behavioral outcomes. The eREACH study evaluates the effectiveness of an interactive, patient-centered digital intervention to deliver clinical genetic testing to patients with metastatic cancers. We expect that this work will inform evidence-based guidelines and the standard of care for delivery of genetic testing, and it is designed to be broadly applicable and easily adaptable for other populations and settings even beyond oncology. Trial Registration: ClinicalTrials.gov NCT04353973; https://clinicaltrials.gov/study/NCT04353973 International Registered Report Identifier (IRRID): DERR1-10.2196/72515